PTC Therapeutics PTCT Business Segments — Labor And Related Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LaborAndRelatedExpense.
The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about PTC Therapeutics's business segments — labor and related expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is PTC Therapeutics's business segments — labor and related expense?
- PTC Therapeutics (PTCT) reported business segments — labor and related expense of $76.12M in Q1 2026.
- How has PTC Therapeutics's business segments — labor and related expense changed year-over-year?
- PTC Therapeutics's business segments — labor and related expense increased by 12.4% year-over-year, from $67.7M to $76.12M.
- What is the long-term trend for PTC Therapeutics's business segments — labor and related expense?
- Over 3 years (2022 to 2025), PTC Therapeutics's business segments — labor and related expense has grown at a -1.7% compound annual growth rate (CAGR), from $298.72M to $283.58M.
- What does business segments — labor and related expense mean?
- This includes all compensation, benefits, and payroll-related costs for personnel directly supporting the operations of the life science segment. It serves as a key indicator of the human capital investment required to sustain research, development, and commercial activities.